Insight Synthesis — CDL Nuclear

1. What CDL Sells

CDL Nuclear sells the end-to-end ability to do cardiac PET imaging — not equipment alone, but a complete service that includes suite construction, equipment procurement, Rb-82 isotope supply through their subsidiary CardioNavix, radioactive materials licensing, staffing, physician training, accreditation support, PACS integration, and billing assistance. Their tagline: "From planning to scanning in 180 days."

Three deal types with different economics and timelines

Fixed-site installation: CDL constructs a dedicated PET suite. The hospital provides staff, obtains its own radioactive materials license. Highest investment, longest timeline (~180 days), largest revenue per deal.

Mobile trailer deployment: CDL provides a PET trailer on a scheduled basis with everything. Lower barrier because the facility doesn't build anything or hire specialized staff.

CardioNavix isotope-only: When a facility already has a PET camera on-site, CDL supplies Rb-82 through CardioNavix. The fastest path to new revenue.

Research context on CardioNavix

The Rb-82 generator market has exactly two FDA-approved products: Bracco's CardioGen-82 (since 1989) and Jubilant's RUBY-FILL (since 2016). CardioNavix is a logistics and delivery business.

Sources: Anchor Note 1, 0686/0733, Anchor Note 4, research q6

2. How CDL Targets Facilities

CDL evaluates facilities through a sequence of questions where each answer determines the deal type, timeline, team, and urgency.

Phil's four qualifying data points

Phil assesses any facility through four procedure volume indicators. These four numbers determine if an account is worth a meeting.

Indicator	Code(s)	What it tells CDL
Cardiac SPECT	78452	Proven cardiac imaging demand — established workflows and patient demand
Cardiac PET	78431, 78492	Whether anyone has gotten there first. Zero = greenfield.
Oncology PET	78815, 78812	Whether a PET camera is on-site (the CardioNavix play)
CCTA	75574	Progressive facility with active cardiology referral infrastructure

The seven facility buckets

Applying Phil's four indicators plus CON status and competitive presence produces seven targeting buckets across 12,045 relevant facilities. After filtering to greenfield targets above the field qualification floor: 1,343 high-priority targets.

Sources: 0903, 0686, 0733, 1133, 0960, 1306

10. Confirmed Patterns and Open Questions

Patterns verified across 3+ independent sources, and questions that remain open after synthesis.

Pattern	Sources	Confidence
Claims data underreports by 50-100%	Dale, Patrick, Phil, Robb	Very high
CCTA signals progressive facility	Lynette, training sessions, Phil	High
Workflow speed determines adoption	Lynette, Rob, Phil, Jessica, Patrick	Very high
Phil as internal champion + single point of failure	Training sessions, multiple calls	Very high
Bottom-up hospital motion	Cole, Phil, Todd	Very high
PET adoption accelerating	Phil, PET share data, ASNC 2026	Very high

Open questions

CardioNavix per-dose pricing — Phil says competitors' margins are "ridiculous," implying CDL undercuts. Actual pricing not in any transcript.
The 60% SPECT-to-PET conversion rate — methodology and provenance unspecified.
Rob's direct voice — we have reports of his frustration but no direct transcript.
No BDM-to-prospect transcripts — all 39 calls are CDL-to-MedScout.

Sources: Cross-referenced across all sessions

Methodology

This synthesis draws from:

6 BA-reviewed anchor notes — manually corrected, contextually annotated
33 DDX transcripts — 12 extracted directly, 10 by calibrated agents
6 outside-in research investigations with primary-source verification
Phil's targeting list (12,767 facilities) analyzed through CDL's own targeting logic

Inside-out evidence (what CDL told us) and outside-in evidence (what we verified independently) are integrated at each section. Where research confirmed, corrected, or extended CDL's claims, this is stated explicitly.